·   Log in

Pollen-derived Oralair to treat allergic conjunctivitis is promising: Stallergenes

Thursday, April 22, 2010, 6:18 This news item was posted in Clinical Trials category and has 0 Comments so far.

Oralair, an experimental drug to treat allergic rhino-conjunctivitis by Stallergenes, has been found highly promising in late phase clinical studies.

The Oralair active substance consists of five purified and calibrated pollen extracts corresponding to the epidemiological characteristics of patient exposure in Europe: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum).

Stallergenes S.A. announced the first results of a phase III clinical trial conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair.

The VO61.08 study is a randomized, double-blind, placebo-controlled, phase III trial. It included 473 adult patients, aged 18 to 65 years, suffering from grass pollen-induced rhinoconjunctivitis, in 51 centers in the United States.

The patients were divided into two arms: one group was treated with Oralair and the other with a placebo. The primary endpoint was the reduction of the “combined score”, taking into account symptoms and rescue drugs.

The study achieved its objective on the primary endpoint: the reduction of the combined score obtained by Oralair compared to the placebo is statistically very significant and of a similar magnitude to the results of European studies. The product was very well tolerated.

“We are proud to have conducted this study in the USA and very satisfied with the results obtained which confirm the high level of evidence in support of Oralair” commented Albert Saporta, chairman and CEO of Stallergenes.

Stellegenes plans to fie a Market Authorization application in early 2011.

Stallergenes has recently announced the positive 3-year results of a phase III clinical trial (VO53.06) intended to assess the long-term or sustained effect of Oralair along with maintenance of the therapeutic benefit after treatment discontinuation (disease-modifier effect).

This study is the first ever pivotal study designed to measure this dual effect from the outset. It will continue for 2 years without treatment so that the disease-modifier effect can be fully assessed.

This phase III study is the first clinical study in the USA to be conducted by Stallergenes as part of the Oralair clinical development which already encompassed 4 phase III clinical trials conducted in Europe.

The development program has so far included over 2,300 patients. This study is pivotal in the perspective of a market authorization application for Oralair in the USA with an adult indication.

Stalair is the pharmaceutical and clinical development program for immunotherapy tablets being implemented by Stallergenes with a view to obtaining market authorizations for pharmaceutical products in Europe and in other strategic markets.

Oralair is the first project resulting from this program. A Mutual Recognition Procedure has been completed in Europe.

A positive phase IIb/III study was completed for the dust mite immunotherapy tablet, Actair in allergic rhinitis in adults during the first half of 2009. A pediatric phase III study has been launched.

The Bet v 1 tablet (birch pollen recombinant) has been the subject of a positive phase IIb/III clinical trial conducted in allergic rhinitis caused by birch pollen. A confirmatory phase III study is currently being prepared with a view to EMA registration.

The other allergens concerned by the program are ragweed for the North American market and Japanese cedar pollen for the Japanese market. Altogether, the program covers 80% of the epidemiology for all markets.

Stallergenes is a European biopharmaceutical company developing immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma.

Stallergenes is the seventh-ranked French pharmaceutical company. A pioneer and leader in sublingual immunotherapy treatments.

Stallergenes devotes over 20% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2009, the company had a turnover of 193 million euros and more than 500,000 patients were treated with Stallergenes products.

Scroll down to comment on this story
You can leave a response, or trackback from your own site.

Leave a Reply